Daniel Xu advises corporate clients on cross-border M&A and investment transactions, with particular focus on foreign direct investments in China, outbound M&A by Chinese buyers, private equity, joint ventures, and other corporate matters. Daniel has advised clients from a wide range of industries such as media, automotive, education, health care, real estate, internet and high-tech, energy, and natural resources. He also has experience on acquisition and servicing of portfolios of nonperforming loans (NPLs).
Daniel's recent experience includes: Cardinal Health's $1.2 billion sale of its China business to Shanghai Pharmaceuticals Holding Co., Ltd.; advising Glencore Singapore Pte. Ltd. on the formation of Zhejiang Petroleum Trading Co., Ltd., a joint venture with Zhejiang Provincial Petroleum Co., Ltd.; advising a state-owned enterprise on its acquisition of a portfolio of PV solar generation facilities in California; advising a U.S. asset management company on their acquisition and servicing of distressed assets in China; and HNA's acquisition of a Hong Kong listed company.
Daniel is fluent in English and a native speaker of Mandarin Chinese.
- Columbia University (LL.M. 2014); East China University of Political Science and Law (LL.M. 2009); East China Normal University (LL.B. 2006)
- New York
- Chinese, English